127 related articles for article (PubMed ID: 8002094)
1. Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.
Bergeron MG; Bernier M
Infection; 1994; 22(4):299-305. PubMed ID: 8002094
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
3. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
4. [In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals].
Sader HS; Mendes CM; Montelli A; Sampaio J; Segura AJ; Kesselring GL; Costa L; Ribeiro JE; Mamizuka E; Mimiça I
Rev Assoc Med Bras (1992); 1998; 44(4):283-8. PubMed ID: 9852647
[TBL] [Abstract][Full Text] [Related]
5. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
6. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
7. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group.
Chamberland S; L'Ecuyer J; Lessard C; Bernier M; Provencher P; Bergeron MG
Clin Infect Dis; 1992 Oct; 15(4):615-28. PubMed ID: 1420674
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin.
Toyosawa T; Miyazaki S; Tsuji A; Yamaguchi K; Goto S
Antimicrob Agents Chemother; 1993 Jan; 37(1):60-6. PubMed ID: 8431019
[TBL] [Abstract][Full Text] [Related]
11. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.
Reeves DS; Bywater MJ; Holt HA
J Antimicrob Chemother; 1993 Mar; 31(3):345-62. PubMed ID: 8486569
[TBL] [Abstract][Full Text] [Related]
12. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Cabezudo I; Pfaller M; Bale M; Wenzel R
Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
[TBL] [Abstract][Full Text] [Related]
13. [Activity of cefpirome against bacteria isolated from hospitalized patients].
Fernández A; Herran I; de Mier C; Marcenac FM
Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
Tumah HN
Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
[TBL] [Abstract][Full Text] [Related]
15. The antimicrobial activity in vitro of cefpirome and 6 other beta-lactam antibacterial agents against clinical isolates.
Yoshimura H; Kosaka Y; Hayashi T; Kawahara S
Jpn J Antibiot; 1993 Oct; 46(10):877-83. PubMed ID: 8254889
[TBL] [Abstract][Full Text] [Related]
16. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.
Paradis D; Vallée F; Allard S; Bisson C; Daviau N; Drapeau C; Auger F; LeBel M
Antimicrob Agents Chemother; 1992 Oct; 36(10):2085-92. PubMed ID: 1444289
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin.
Marton A; Major P
Microb Drug Resist; 1996; 2(3):361-9. PubMed ID: 9158796
[TBL] [Abstract][Full Text] [Related]
20. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
